Momenta Phama (MNTA) Misses Q4 EPS by 29c, Revenues Beat

Momenta Phama (NASDAQ: MNTA) reported Q4 EPS of ($0.85), $0.29 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $8.18 million versus the consensus estimate of $5.56 million.

“2019 was a transformative year for Momenta as the power of our pipeline began to show itself,” said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. “Thanks to our talented research team, we are also expanding our pipeline, starting with the nomination of M267, our new SIFbody development candidate earlier this year.”

For earnings history and earnings-related data on Momenta Phama (MNTA) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Ideal Power (IPWR) Tops Q2 EPS by 2c
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02